What Researchers Did
Researchers retrospectively compared 48 patients with idiopathic sudden sensorineural hearing loss who received secondary hyperbaric oxygen therapy with 44 control patients who received conventional treatment alone to assess HBOT's efficacy in subacute and chronic phases.
What They Found
The mean hearing gain was 5.2 dB in the hyperbaric oxygen therapy group and 2.0 dB in the control group, but this difference was not statistically significant. No significant difference in hearing gain was observed based on the timing of HBOT initiation. However, patients with profound hearing loss showed significantly higher hearing gain.
What This Means for Canadian Patients
Canadian patients with sudden sensorineural hearing loss in subacute or chronic phases should be aware that secondary hyperbaric oxygen therapy may not offer significant additional benefit. Decisions regarding this treatment should be made cautiously, considering the unproven effectiveness for most patients.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
As a retrospective study, it is subject to inherent limitations such as potential selection bias and reliance on existing medical records.